Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Revue Des Maladies Respiratoires|August 12, 2003
[EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma]A-P Meert, B Martin, J-M Verdebout, et al.
Histopathology|January 14, 2004
Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary studyA-P Meert, F Feoli, B Martin, et al.
The European Respiratory Journal|May 16, 2008
The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinomaC Mascaux, F Bex, B Martin, et al.
Thorax|May 1, 1997
Superior vena cava syndrome associated with Nocardia farcinica infectionS Abdelkafi, D Dubail, T Bosschaerts, et al.
Anticancer Research|August 10, 2002
Expression of thrombospondin in non-small cell lung cancerC Mascaux, B Martin, M Paesmans, et al.
Pflugers Archiv : European Journal of Physiology|February 1, 1988
Vasoconstrictive effect of portal blood in isolated dog kidneyN Bourgeois, C Reuse, M Gelin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2000
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. 101473.1044@compuserve.comJ P Sculier, J J Lafitte, T Berghmans, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapyJ P Sculier, T Berghmans, J J Lafitte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancerJ P Sculier, J J Lafitte, J Lecomte, et al.
Cancer|August 10, 2000
Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 yearsM Paesmans, J P Sculier, J Lecomte, et al.
Pageof 10